Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

被引:181
作者
Bjorkman, Sven [1 ]
Oh, MyungShin [2 ]
Spotts, Gerald [2 ]
Schroth, Phillip [2 ]
Fritsch, Sandor [3 ]
Ewenstein, Bruce M. [2 ]
Casey, Kathleen [2 ]
Fischer, Kathelijn [4 ,5 ]
Blanchette, Victor S. [6 ,7 ]
Collins, Peter W. [8 ]
机构
[1] Uppsala Univ, Dept Pharmaceut Biosci, SE-75124 Uppsala, Sweden
[2] Baxter Healthcare Corp, Westlake Village, CA USA
[3] Baxter Innovat GmbH, Vienna, Austria
[4] Univ Med Ctr, Van Creveldklin, Utrecht, Netherlands
[5] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[6] Univ Toronto, Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada
[7] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada
[8] Cardiff Univ, Univ Wales Hosp, Sch Med, Arthur Bloom Haemophilia Ctr,Dept Haematol, Cardiff, S Glam, Wales
关键词
COAGULATION-FACTOR VIII; PROPHYLACTIC TREATMENT; FACTOR-IX; PLASMA; VARIANCE; STANDARD; CHILDREN; RECOVERY; EFFICACY; SAFETY;
D O I
10.1182/blood-2011-07-360594
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Comparison of the pharmacokinetics (PK) of a coagulation factor between groups of patients can be biased by differences in study protocols, in particular between blood sampling schedules. This could affect clinical dose tailoring, especially in children. The aim of this study was to describe the relationships of the PK of factor VIII (FVIII) with age and body weight by a population PK model. The potential to reduce blood sampling was also explored. A model was built for FVIII PK from 236 infusions of recombinant FVIII in 152 patients (1-65 years of age) with severe hemophilia A. The PK of FVIII over the entire age range was well described by a 2-compartment model and a previously reported problem, resulting from differences in blood sampling, to compare findings from children and adults was practically abolished. The decline in FVIII clearance and increase in half-life with age could be described as continuous functions. Retrospective reduction of blood sampling from 11 to 5 samples made no important difference to the estimates of PK parameters. The obtained findings can be used as a basis for PK-based dose tailoring of FVIII in clinical practice, in all age groups, with minimal blood sampling. (Blood. 2012; 119(2): 612-618)
引用
收藏
页码:612 / 618
页数:7
相关论文
共 30 条
[11]   Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years [J].
Bjorkman, Sven ;
Folkesson, Anna ;
Jonsson, Siv .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (10) :989-998
[12]   Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients [J].
Blanchette, V. S. ;
Shapiro, A. D. ;
Liesner, R. J. ;
Navarro, F. Hernandez ;
Warrier, I. ;
Schroth, P. C. ;
Spotts, G. ;
Ewenstein, B. M. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (08) :1319-1326
[13]   A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A [J].
Bolon-Larger, Magali ;
Chamouard, Valerie ;
Bressolle, Francoise ;
Boulieu, Roselyne .
THERAPEUTIC DRUG MONITORING, 2007, 29 (01) :20-26
[14]   Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A [J].
Carlsson, M ;
Berntorp, E ;
Bjorkman, S ;
Lethagen, S ;
Ljung, R .
HAEMOPHILIA, 1997, 3 (02) :96-101
[15]   Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia [J].
Collins, P. W. ;
Fischer, K. ;
Morfini, M. ;
Blanchette, V. S. ;
Bjorkman, S. .
HAEMOPHILIA, 2011, 17 (01) :2-10
[16]   Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens [J].
Collins, P. W. ;
Bjorkman, S. ;
Fischer, K. ;
Blanchette, V. ;
Oh, M. ;
Schroth, P. ;
Fritsch, S. ;
Casey, K. ;
Spotts, G. ;
Ewenstein, B. M. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (02) :269-275
[17]  
Food and Drug Administration, GUID IND POP PHARM
[18]   A size standard for pharmacokinetics [J].
Holford, NHG .
CLINICAL PHARMACOKINETICS, 1996, 30 (05) :329-332
[19]   Population pharmacokinetics of recombinant factor VIII:C (ReFactoA®) in adult HIV-negative and HIV-positive haemophilia patients [J].
Karafoulidou, Anastasia ;
Suarez, Elena ;
Anastasopoulou, Ioanna ;
Katsarou, Olga ;
Kouramba, Anna ;
Kotsi, Paraskevi ;
Zografidis, Anastasios ;
Lukas, John C. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (11) :1121-1130
[20]   THE IMPORTANCE OF MODELING INTEROCCASION VARIABILITY IN POPULATION PHARMACOKINETIC ANALYSES [J].
KARLSSON, MO ;
SHEINER, LB .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1993, 21 (06) :735-750